Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
- Citation:
- NPJ Breast Cancer vol 8 (1) 68
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub-ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 11
- Parents:
- 2906
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA232760, UG1CA233373, W81XWH-18-1-0562 and -0563, W81XWH-16-1-0265 and 0266, BCRF-19-16, Bankhead-Coley Research Program (6BC05), Roche
- Corr. Author:
- Authors:
- Saranya Chumsri Zhuo Li Daniel J. Serie Nadine Norton Afshin Mashadi-Hossein Kathleen Tenner Heather Ann Brauer Sarah Warren Patrick Danaher Gerardo Colon-Otero Ann H. Partridge Lisa A. Carey Florentine Hilbers Veerle Van Dooren Eileen Holmes Serena Di Cosimo Olena Werner Jens Bodo Huober Amylou C. Dueck Christos Sotiriou Cristina Saura Alvaro Moreno-Aspitia Keith L. Knutson Edith A. Perez E. Aubrey Thompson
- Networks:
- LAPS-MA036, LAPS-MN026, LAPS-NC007, NY021, PR028
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: